Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the 10 affordable biotech stocks to buy right now.
On June 24, Taysha Gene Therapies Inc. (NASDAQ:TSHA) disclosed the pricing of an underwritten public offering of 32.5 million of its common stock, priced at $6 per share
The offering also involved prepaid warrants to buy 833,333 shares at $5.999 per warrant. Pixabay/Public domain The company anticipates gross proceeds of around $200 million before accounting for underwriting commissions, discounts, and expenses, not including any underwriters’ option exercise. The company has granted the underwriters a 30-day option to buy up to an additional 5 million common shares.
On June 23, Bank of America Securities increased its target price on Taysha Gene Therapies Inc. (NASDAQ:TSHA) from $9 to $10, leading to an adjusted upside potential of more than 57%. The firm maintained a Buy rating on the stock following the company’s update regarding the Part A REVEAL study to evaluate TSHA-102 in Rett syndrome. The firm stated the data supports the position of TSHA-102 as the earliest available disease-modifying treatment for Rett syndrome.